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Rapid and correct diagnosis of acute myocardial infarction (AMI) plays a crucial role in saving patients’ life. Although some
biomarkers (such as cardiac troponin and creatine kinase) are available for AMI diagnosis so far, there is still a clinical need for
novel biomarkers, which can reliably rule in or rule out AMI immediately on admission. Circulating microRNAs (miRNAs) are a
potentialchoicefornovelbiomarkersinAMIdiagnosisandprognosiswithhighsensitivityandspecificity.CirculatingmicroRNAs
are endogenous miRNAs that are detectable in whole blood, serum, or plasma in a highly stable form. Until now, around 20
circulating miRNAs were reported to be closely associated with AMI. In this minireview, we summarized recent available data
on the correlation between circulating miRNAs and AMI. Some miRNAs, such as miR-208, miR-499, miR-133, and miR-1, were
given special attention, since they may have a potential prospect in diagnosis and prognosis of AMI.
1. Introduction
Coronary artery disease (CAD) is a very common health
problem in the developed as well as developing countries.
Acute myocardial infarction (AMI) is one of the leading
c a u s e sf o rd e a t hw o r l d w i d e ,a n di ti st h es i n g l el a r g e s tc a u s e
of death in the United States, responsible for 1 out of every
6d e a t h s[ 1, 2]. Rapid and correct diagnosis of AMI plays
an important role in therapy and prognosis for this disease.
Over the past two decades, huge progress has been made in
the diagnosis, treatment, and prognosis of AMI. Particularly,
the progress in biomarkers for AMI attracted a great deal of
attention. Currently, cardiac troponins are the most common
biomarkers used for diagnosis of AMI in clinical practice.
However, there is still a clinical need for novel biomarker,
which is able to reliably rule in or rule out AMI immediately
onadmission.MicroRNAs(miRNAs)seemtobeapromising
candidate of novel biomarker for early diagnosis of AMI [3].
In the last few years, the dysregulation of tissue expression
levels of miRNAs has been directly linked to cardiac disease.
In addition to expression changes in tissues, more recent
studies have indicated that miRNAs are detectable in serum,
plasma, urine, and other body fluids in a highly stable form
thatisprotectedfromendogenousRNaseactivity[4].Altered
circulating miRNA concentrations have been detected in
patients with AMI [5], acute coronary syndrome (ACS) [6],
stable coronary artery disease [7], heart failure [8], coronary
atherosclerosis, cardiac arrhythmia, cardiomyopathy, and
cardiac hypertrophy [9] .Th i sr ev i eww i l lf ocu so napo t e n t i a l
role of circulating miRNAs in diagnosis of AMI as novel
biomarkers.
2. Circulating miRNAs
miRNAs are endogenous, small (∼22 nucleotides), single-
stranded, noncoding RNAs that regulate gene expression at
theposttranscriptionallevelbybindingtothe3
򸀠 untranslated
regions (UTRs) of their target mRNAs [10]. When miRNAs
completely bind to their target mRNAs, degradation of562 Disease Markers
the target mRNAs will be initiated. But, when the miRNAs
bind partially, the translation of mRNA is repressed. miR-
NAs are involved in multiple biological processes, such as
proliferation,migration,differentiation,secretion,excitation,
conduction, cell cycle, ageing, and apoptosis, by changing
protein expression of potential candidate targets [11].
miRNAshaverecentlybeendetectedinserumorplasma,
which are referred to circulating miRNAs. Despite intense
research, the origin of circulating miRNAs remains largely
unknown. A number of studies have reported that miRNAs
are actively secreted in microvesicles or exosomes from
differentcelltypes[12],whicharealikelysourceofcirculating
miRNAs. So far, around 121 miRNAs were identified in
exosomes from mast cells [13], and sphingomyelinase 2
(nSMase2),arate-limitingenzymeforceramidebiosynthesis,
controlsthesecretionofexosomes to the extracellularmatrix
[14].Inadditiontomicrovesiclesorexosomes,microparticles
and lipoprotein complexes (such as high-density lipoprotein
complexes)areotherpossiblesourcesofcirculatingmiRNAs.
Microparticles are larger than exosomes of plasma mem-
brane origin, contain miRNAs, and actively control cell com-
municationprocess[15].High-densitylipoprotein(HDL)has
been reported to transport endogenous miRNAs and deliver
them to recipient cells with functional targeting capabilities
besides its basic role as a delivery vehicle for excess cellular
cholesterol. Interestingly, the human HDL-miRNA profile
from normal subjects is significantly different than familial
hypercholesterolemia subjects. The most abundant miRNAs
a s s o c i a t e dw i t hH D Lf r o mn o r m a ls u b j e c t sw e r eh s a - m i R -
135a, hsa-miR-188-5p, and hsa-miR-877, whereas the most
abundant familial hypercholesterolemia HDL-miRNAs were
hsa-miR-223, hsa-miR-105, and hsa-miR-106a. Therefore,
human HDL not only transports endogenous miRNAs, but
alsocandisplaydifferentfunctionsunderdifferentconditions
andactaspotentialmediatorsingeneregulationandintercel-
lular communication. The detection of circulating miRNAs
in the plasma and serum indicates that miRNAs may fulfill
biological functions outside the cell and act as potential
biomarkersfordiseases[16].Thehumangenomeisestimated
toencodeupto1000miRNAsandover100miRNAsinserum
were identified from healthy subjects [17].
3. Stability and Isolation of
Circulating microRNAs
H u m a nm i R N A si s o l a t e df r o mp l a s m aa r eh i g h l ys t a b l e
in boiling water, in solution with very high or low pH.
Plasma miRNA levels remain stable when it is subjected to
prolonged room temperature incubation or freeze-thawed
multiple times. It has been reported that endogenous plasma
miRNAs exist in a form that is resistant to plasma RNase
activity [18]. Compared to the endogenous plasma miR-
NAs, rapid degradation was observed within minutes when
synthetic miRNAs (corresponding to caenorhabditis elegans
miRNAs cel-miR-39, cel-miR-54, and cel-miR-238) were
added into human plasma. Inactivating the RNase activ-
ity before the addition, the exogenous miRNAs escaped
degradation. Therefore, exogenous plasma miRNAs are not
stable and are susceptible to rapid degradation, whereas
native circulating miRNAs are stable and resistant to RNase
activity [19]. There are multiple factors that account for the
protection of circulating miRNAs against RNase-dependent
degradation. For example, circulating miRNAs are not free
in blood, which are normally included in microvesicles or
exosomes. Furthermore, the circulating miRNAs can form
the protein-miRNA complexes with some special proteins
(such as nucleolar RNA-binding protein, nucleophosmin 1)
to resist the degradation [20].
Although circulating microRNAs are stable, reproducible
isolation of cell-free miRNAs with high purity is a techni-
c a lc h a l l e n g ef o rm u l t i p l er e a s o n s .F i r s t ,p l a s m ao rs e r u m
contains very low amounts of RNA. The yield of RNA
from small volume of plasma or serum (usually less than
1mL) falls below the limit of accurate quality control by
regular methods. Second, high concentration of proteins in
plasma or serum could potentially interfere with the sample
preparation and the detection assay. Thus, avoiding protein
contamination and hemolysis (lysis of red blood cells) in
serum/plasmasamplesareimportantchallengestoovercome.
Finally, some of the larger small RNA species frequently
used as reference genes (such as U6 RNA, cel-miR-39) to
normalize the data of qPCR are present in extremely low
concentrationsinserumorplasma.Therefore,greatcaremust
be taken when choosing controls (miR-156 is an option)
for normalization. Fortunately, with circulating microRNAs
wellrecognizedforpotentialdiagnosticbiomarkersinawide
range of diseases and biological processes, more commercial
kits for high quality of circulating microRNAs isolation are
available in the market.
4. Circulating miRNAs of Cardiac Origin and
Acute Myocardial Infarction
Rapid and correct diagnosis is crucial to treatment and
prognosis of AMI. Up to date, cardiac troponins and creatine
kinase-MBarethemostcommonlyusedbiomarkersforAMI,
but their clinical value is limited in many cases. Secreted by
cardiaccellsandaccumulatedinblood,miRNAsareexpected
to reflect cardiac injury in response to cardiovascular risk
factors and various pathological conditions. Thus, the circu-
lating cardiac-specific or -enriched miRNAs (such as miR-
208, miR-499, and miR-133) may provide unique biomarkers
for diagnostic and therapeutic interventions of AMI [21].
4.1. miR-208. miR-208 is a cardiac-enriched microRNA and
found at much higher levels during cardiac tissue injury. It
is also involved in stress, hormone, or electric stimulation in
cardiac cells [22, 23]. During cardiac development, miR-208
exertsaregulatoryroleintheproductionofthemyosinheavy
chain [24]. It has been reported that plasma concentration
of circulating miR-208 levels was significantly increased fol-
lowingisoproterenol-inducedratmodelofmyocardialinjury.
But this phenomenon was not observed after renal injury,
indicating that circulating miR-208 is specific for cardiac
injury. There was a good correlation between the changesDisease Markers 563
in plasma miR-208 and cardiac troponin I (cTnI), a classical
biomarker of AMI [25].
4.1.1.miR-208a. Throughmicroarrayanalysis,miR-208awas
absolutely identified to be expressed in the human heart.
miR-208a was undetectable in plasma of healthy individuals
or non-AMI patients (such as patients with acute kidney
injury, chronic renal failure, stroke, or trauma), but it was
easily detected in 90.9% AMI patients and in 100% AMI
patients within 4h of the onset of chest pain while cTnI
was not yet affected, suggesting that miRNAs may leak into
the bloodstream at an earlier stage of myocardial injury
(the biological peak of troponins is ∼18h after AMI). It
is reasonable to speculate that circulating miR-208a has
advantages over cTnI (or cTnT) in distinguishing pure AMI
from patients with renal disease, stroke, and trauma [5].
Interestingly, the elevation of circulating miR-208a in
AMI could be persistent in adult mouse but not in human.
A possible explanation for this phenomenon might be due
to the different miRNA expression pattern between human
and mice. miR-208a is encoded within an intron of 𝗼-cardiac
muscle myosin heavy chain gene (Myh6), while miR-208b, a
closefamilymemberofmiR-208,isencodedwithinanintron
of 𝗽-cardiac muscle myosin heavy chain gene (Myh7). There
exists high degree of homology between miR-208a and miR-
208binmicebutnotinhuman.Itislikelythatthepersistently
elevated plasma level of miR-208a after AMI might be the
result of miR-208b interference [23].
4.1.2. miR-208b. In case of acute ST segment elevation
myocardial infarction (STEMI) patients, the levels of plasma
miR-208b increased 3,000-fold compared to healthy controls
within 12h after infarction. Peak values of miR-208b were
well correlated with peak troponin I (cTnI) and the ejection
fraction, indicating a possible role for circulating miR-208b
as a biomarker in diagnosis of STEMI or in prediction
of long-term complications [26]. In AMI patients, plasma
miR-208b was increased 1600-fold compared with healthy
subjects. The receiver operating characteristic (ROC) curve
analysisrevealedanareaundertheROCcurve(AUC)of0.94,
suggesting that miR-208b was an ideal biomarker for AMI.
ThechangesinplasmalevelofmiR-208bwereconsistentwith
plasma troponin-T, indicating that miR-208b was released
from injured cardiomyocytes like troponin-T [27]. However,
itisnotallofthestudiesthatsupportedtheroleofmiR-208as
a biomarker for AMI. Adachi et al. reported that circulating
m i R - 2 0 8 bl e v e la p p e a r e dt ob ev e ryl o wi nA M Ip a t i e n t s ,a n d
it was a useful plasma biomarker for AMI diagnosis [28].
Another study has recently demonstrated that circulating
miR-208b might be used as a biomarker for AMI but it did
not show any advantages over cTNT for AMI diagnosis [29].
4.2. miR-499. The gene encoded miR-499 is embedded
withinaventricular-specificmyosinheavychaingene,which
is almost exclusively expressed in the heart [30]. Plasma level
of miR-499 was obviously increased in all patients with AMI
butitwasbelo wthelimitofdetectionforacutecoronarysyn-
dromes, congestive heart failure, and for all healthy controls.
These results indicated that circulating miR-499 might be a
useful biomarker for the diagnosis of AMI [28]. It has been
demonstrated that plasma level of miR-499 increased 250-
fold or 100-fold in patients with acute STEMI or AMI com-
paredwithhealthycontrols[26].ROCcurveanalysisrevealed
an area under the curve of 0.92, which is correlated with
circulating cTnT. In AMI patients with chest pain <3h,miR -
499 was positive in 93% of patients while the positive rate
for hs-cTnT was 88%, suggesting that miR-499 is a sensitive
and novel biomarker for the diagnosis of AMI [31]. However,
r e s ul t so fR OCcu rv ea n al y s i sfr o mLie tal . ’ ss t u d ys h o w e dn o
advantage for plasma miR-499 over cTNT in AMI diagnosis.
Circulating miR-499-5p, a family member of miR-499,
was increased more than 80-fold in geriatric patients with
acute non-ST elevation myocardial infarction (NSTEMI)
compared with healthy subjects. The ROC curve analysis
showed that diagnostic accuracy of miR-499-5p was higher
than that of TNT (AUC of miR-499-5p versus cTnT versus
hs-cTnT:0.86versus0.68versus0.70).Thus,circulatingmiR-
499-5p is a potential biomarker and its accuracy is superior
to conventional cTnT for the diagnosis of acute NSTEMI in
the elderly patients [32]. Recently, a study demonstrated that
miR-499-5p was higher in MI patients and was negatively
correlated with the value of left ventricular ejection fraction,
strongly suggesting that circulating miR-499-5p might be
used for the evaluation of mortality risk [33].
4.3. miR-133. I nar a tA M Im o d e l ,p l a s m al e v e lo fm i R -
1 3 3 aw a si n c r e a s e da t1 – 3h ,p e a k e da t3 – 1 2h ,a n dd e c r e a s e d
at 12–24h after coronary artery ligation. In AMI patients,
miR-133plasmalevelwassubstantiallyhighercomparedwith
healthy controls. A positive correlation was also reported
betweentheelevatedplasmamiR-133andcTNI.Theseresults
provided evidence that miR-133 is a powerful biomarker for
thediagnosisofAMI[5].However,thereweresomedifferent
reports on circulating miR-133. In a report, no significant
differenceinplasmalevelofmiR-133hadbeenfoundbetween
AMI patients and healthy subjects [34]. Circulating miR-
133 also showed no significant changes in AMI patients
withtachyarrhythmiaorbradyarrhythmiacomparedtothose
in patients without arrhythmias. Plasma levels of miR-133a
and miR-133b, family members of miR-133, were reported
to be upregulated in acute STEMI patients compared with
healthy subjects, which was peaked at about 156 minutes
after occurrence of infarction, consistent with time course of
changeincTNIlevel.Incontrast,thelevelofcirculatingmiR-
133a was not significantly changed in mice subjected to acute
hind-limb ischemia [35].
4.4. miR-1. The plasma level of miR-1 was reported to
markedly increased in rats with AMI or in AMI patients,
which was only mildly increased in patients with non-AMI
coronary heart disease or patients with other cardiovascular
diseases [5]. In a rat model of AMI induced by coronary
ligation,serummiR-1levelwasrapidlyincreasedaround200-
foldafterAMIwithapeakat6h,andthemiR-1levelreturned
to basal levels at 3 days after AMI, which displayed a strong
positive correlation with myocardial infarct size. In a clinical564 Disease Markers
Table 1: Summary of circulating miRNAs and AMI.
miRNAs Diseases Species Upregulation/downregulation Correlation with cardiac troponin Reference
miR-208a AMI Human Up Positive [5]
miR-208a AMI Rat Up [23]
miR-208b
Acute STEMI Human Up Positive [26]
AMI Human Up [27]
AMI Human Up Positive [29]
miR-499
Acute STEMI Human Up Positive [26]
AMI Human Up Positive [31]
NSTEMI Human Up Positive [32]
AMI Human Up [29]
AMI Human Up [33]
miR-133
AMI Rat Up [5]
AMI Human UP [35]
AMI Human Up Positive [38]
miR-1
AMI Rat Up [5]
AMI Human, rat Up [36]
AMI Human Up Positive [34]
AMI Human Up [26]
AMI Human Up [29]
miR-328 AMI Human Up Positive [43]
miR-1291 AMI Human Up [36]
miR-21 AMI Human Up [44]
miR-30, miR-195 AMI Human Up [45]
miR-let-7b AMI Human Down [45]
miR-378 AMI Rat Down [46]
miR-126 AMI Human Down [40]
AMI: acute myocardial infarction; STEMI: ST segment elevation myocardial infarction; NSTEMI: non-ST segment elevation myocardial infarction.
study, the level of circulating miR-1 was increased nearly 100-
fold in AMI patients compared with healthy subjects and
showed a positive correlation with serum creatine kinase-
MB(CK-MB)level.Inanotherseparateclinicalstudy,plasma
miR-1 level was significantly higher in AMI patients com-
pared with non-AMI subjects and the level was returned
to normal on discharge following medication. Interestingly,
the increased plasma miR-1 was not associated with age,
gender,bloodpressure,diabetesmellitus,orotherestablished
biomarkers for AMI including cTnI and CK-MB. Moreover,
inanecrosismodelofculturedcardiaccells,miR-1wasfound
to be released into the culture medium and was stable at
least for 24h. Collectively, these results strongly support that
circulating miR-1 might be a novel sensitive biomarker for
AMI diagnosis [36].
5. Circulating miRNAs of Noncardiac Origin
and Acute Myocardial Infarction
In theory, the change of circulating miRNAs after AMI is
due to the injured heart, which releases miRNAs into the
blood.However,thereisevidencetoshowthatmanychanges
in circulating miRNAs may not originate from the injured
heart. In a recent study, whole-genome miRNA expression
in peripheral total blood samples from AMI patients was
analyzedand121miRNAswerereportedtobedysregulatedin
comparison to healthy controls. Among them, miR-30c and
miR-145 levels were found to be correlated with infarct size,
miR-1291 and miR-663b were highly sensitive and specific
for the discrimination of cases from controls, and a unique
signa tur eof20miRN A swassho wntopr edictAMIwitheven
higher power (specificity 96%, sensitivity 90%, and accuracy
93%) [37]. These results indicate that miRNA signatures
derived from peripheral blood cells could be also used as
novel, sensitive biomarkers for the diagnosis of AMI.
miR-126 is specifically and highly expressed in human
endothelialcells.It hasapotentialroleinangiogenesisandin
regulation of endothelial homeostasis and vascular integrity
[38, 39]. Circulating plasma miR-126 was significantly down-
r e g u l a t e di nA M Ip a t i e n t sc o m p a r e dw i t hh e a l t h ys u b j e c t s .
The plasma concentration of miR-126 also showed a good
correlation with the plasma concentration of cTnI in AMI
[40]. Circulating levels of miR-126 were decreased during
transcoronary passage in patients with evidence of myocar-
dial injury compared with noncoronary artery disease [41].
Recently, a prospective study has reported that circulating
miR-126 has a positive association with fatal myocardial
infarction [42].
Sofar,moreandmorecirculatingmiRNAs,cardiacorigin
or noncardiac origin, were reported to be potential biomark-
ers for AMI. Table 1 is a summary of the correlation betweenDisease Markers 565
circulating miRNAs and AMI from the recent literatures. As
displayed in Table 1, at least 13 miRNAs were reported as
potentialbiomarkersforAMI.Amongthem,cardiac-specific
or -enriched miRNAs (such as miR-208, miR-499, miR-133,
a n dm i R - 1 )a t t r a c t e dm o r ea t t e n t i o n[ 25, 27, 28, 34]. Since
miR -208andmiR -499wereonlydetectedinheartwhilemiR -
133 and miR-1 were highly expressed in both skeletal and
cardiac muscle,intheory,miR-208andmiR-499 shouldhave
the advantages (such as more specific or sensitive) over miR-
133 and miR-1 in AMI diagnosis. Actually, in Wang et al.’s
study, they examined the plasma levels of miR-208, miR-
499, miR-133, and miR-1 in AMI patients and rat model of
AMI. After careful comparison and analysis of the results,
they concluded that among these four miRNAs, miR-208 is
amorereliablebiomarkerforAMIdiagnosis[5].However,in
Devaux et al.’s study, they provided evidence that circulating
miR-499appearedclearlysuperiortocirculatingmiR-208for
detecting cardiac damage [31]. Thus, it needs further studies
to determine which one (miR-208 or miR-499) is the most
potential biomarker for AMI diagnosis.
6. Conclusion
In summary, circulatingmiRNAs are resistantto endogenous
ribonuclease activity and can be present in human plasma
or serum in a remarkably stable form. It is believed that
circulatingmiRNAsprovideanovelclassofminimalinvasive
biomarkersforAMIdiagnosis.Untilnow,around20miRNAs
were reported as potential biomarkers for AMI. However,
most of the findings were based on relatively small samples,
which lead to many divergences between different reports.
Therefore, it is necessary to conduct independent and large
cohort studies to identify those circulatingmiRNAs with real
v a l u ei nA M Id i a g n o s i s .S of a r ,m o s to ft h es t u d i e sf o c u s
o nt h er o l eo fc i r c u l a t i n gm i R N A sa sb i o m a r k e r sf o rA M I
diagnosis. The information regarding the prognostic impact
ofcirculatingmiRNAsinAMIisstilllargelylacking.Actually,
as ideal biomarkers, it is also important to be useful in AMI
prognosis. Recently, we have found that plasma levels of
miR-208b,miR-499,miR-149,andmiR-424weresignificantly
elevated in AMI. Among them, miR-208b, miR-499, and
miR-424 were rapidly decreasedafter percutaneouscoronary
intervention (PCI) (unpublished data), suggesting that miR-
208b,miR-499,andmiR-424mightbepotentialcandidatesas
biomarkersforAMIprognosis.Itisapossiblefuturedirection
to seek specific circulating miRNAs with potential value in
AMI diagnosis as well as prognosis.
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